Fri, May 17, 2024
Needle-Free Injection System: IntegriMedical has developed a US patented Needle-Free Injection System (N-FIS) that utilizes high-velocity jet stream using mechanical power to effectively and consistently administer biologics and drugs.
More >
Thu, Apr 13, 2023
COVID-19 is trending back in India. India has registered has registered over ten thousand one hundred new cases of COVID-19 in the last 24 hours. Amidst the rising coronavirus cases, Serum Institute of India has restarted manufacturing of COVID-19 vaccine Covishield amid rising numbers of cases of the virus infection. With this, Delhi AIIMS issued its advisory saying that all employees will have to wear face masks/surgical masks at the workplace. How to protect yourself from COVID-19? What did WHO say? Watch this special discussion with Deepak Dobhal on India 360.
Thu, Dec 22, 2022
Covovax was approved by the DCGI for a restricted emergency use in children aged seven to 11 years in June.
Thu, Sep 01, 2022
"The schemes like Ayushman Bharat have made us think about preventive healthcare and we can now afford it. The Department of Biotechnology has taken a lead in the matter and are in collaborative mode," he said.
Wed, Aug 31, 2022
According to World Health Organisation’s (WHO) International Agency for Research on Cancer (IARC-WHO), India records around 1.23 cases of cervical cancer annually and almost 67,000 women die everywhere.
Thu, Jan 27, 2022
DCGI on Thursday gave its nod for market authorization of two COVID-19 vaccines - Covaxin and Covishield subject to certain conditions. Consent came after the the Subject Expert Committee of CDSCO recommended for upgradation of status for vaccines from restricted use in emergency situations to grant of new drug permission
Wed, Jan 26, 2022
The price of Covaxin is at Rs 1,200 per dose as of now while Covishield costs Rs 780 in private facilities. The prices include Rs 150 service charge. Both the vaccines are only authorised for emergency use in the country
Wed, Jan 19, 2022
An expert panel of India's central drug authority on Wednesday recommended granting regular market approval to Covid vaccines Covishield and Covaxin, which are currently only authorised for emergency use in the country, subject to certain conditions, official sources said.
Fri, Dec 31, 2021
Serum Institute Of India has applied to the country`s drug regulator and the health ministry for full approval of its COVID-19 vaccine Covishield, the company`s chief executive said on Friday.
Tue, Dec 28, 2021
India gave emergency use authorisation (EUA) for Merck`s COVID-19 pill molnupiravir, and Serum Institute of India`s Covovax and Biological E`s Corbevax coronavirus vaccines, the country`s health minister said on Twitter.
Wed, Dec 08, 2021
Serum Institute of India (SII), the world`s biggest vaccine maker, will halve the output of the AstraZeneca COVID-19 shot from next week as it had no fresh orders from the government, its CEO Adar Poonawalla told CNBC-TV18 on Tuesday.
Fri, Oct 08, 2021
Adar Poonawalla’s Serum Institute of India may acquire around 10 percent stake in Mumbai based pharma company Wockhardt Limited.
Tue, Aug 17, 2021
The world's largest vaccine maker Serum Institute of India has bought a 50 per cent stake in the Indian joint venture SCHOTT Kaisha from former co-owners Kairus Dadachanji and Shapoor Mistry at an undisclosed amount to expand its presence in pharmaceutical packaging segment.
Tue, Jul 13, 2021
Serum Institute of India (SII) has entered into an agreement with Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, for the production of Sputnik-V COVID-19 vaccine. SII and RDIF said in a joint statement on July 13 that the first batch of Sputnik V vaccine doses are expected to be produced at SII's facilities in September.
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
